How do you fight against the drug prices gouging of drug companies?
Well, the best way is to find the drug’s manufacturer and negotiate a price with them.
The problem is, some drug companies are very quick to take advantage of this tactic.
The latest example is Tetraphase Pharmaceuticals, which is in a war with another company, Salarius Pharmaceuticals.
TetraphASE wants to control the supply of Tetraphace, a rare but highly effective medication that is used to treat seizures in children.
Salarius wants to keep the drug.
Tetrapheres price is too high.
The battle is expected to last at least a year.
Tetrophen is the first drug to be approved for pediatric use, but its price has been raised by more than 200%.
It’s not the only one.
The pharmaceutical industry’s biggest player, Merck, recently raised its price on a number of drugs to as much as $100,000 per month, according to an Associated Press report.
Some drugs, like the life-saving antipsychotic flumazenil, are being offered for less than the cost of the drug itself.
The industry is not alone.
A study from the Brookings Institution, released in June, found that drug companies spend $15.5 billion a year on drugs that are in high demand and can be charged exorbitant prices.
The average price of a drug approved in the United States was about $15,000 a month in the third quarter of this year.
That’s up from $12,000 last year.
It’s a lot to ask for a drug that can treat an average of two to three seizures a day and can have a survival rate of 90% to 100%.
Drug companies have tried many different strategies to keep their prices low.
They’ve increased competition by buying up smaller competitors and making generic versions.
They have sought to reduce the cost by using patents to prevent competition from other companies.
They even bought up patents to protect the patents of their competitors.
But the most popular strategy has been the one they’ve used in this case: The drug companies have gone to court to stop other drug companies from selling the drug and have been successful in stopping those companies from negotiating a lower price.
Tetramax, for instance, has been available for nearly a year in the U.S. and in other countries.
Tetraplast, a cheaper, older, and sometimes less potent version, is available in other European countries, but it’s expensive in the States.
The price for Tetramazol, a different drug, is about $10,000 in the US and Canada.
So the drug companies decided to fight back.
In April, Tetraphen’s maker, Merkem, filed a lawsuit in the Federal District Court for the Northern District of California in San Francisco.
Tetraxan, the older, cheaper version of Tetramacz, was also sued in California, but that case is ongoing.
The company is asking for an injunction to stop the others from selling Tetramix and Tetraptroz.
The injunction could prevent them from negotiating lower prices for Tetraphax.
Tetroxan is being sold at $150,000 to $200,000, according, the company’s website.
Tetraczol, which has a lower dose of Tetraphe, is being offered at $80,000 or $130,000.
Tetrabenzol and Tetraphedra, which have lower doses of Tetraapro, are at $50,000 and $100 and $150 respectively.
They also are being sold in Europe and Asia.
The lawsuit also says Tetraphax, which had its price increased by 100%, is being made available for less money and at a lower dosage in Europe.
Tetranaczol is being priced at $25,000 for the first month, but later will be at $30,000 at its lowest dosage.
The drug is also being sold on Amazon and other sites.
The American Medical Association has already supported Tetraphet’s bid for a lower drug price.
In a statement, the group said the drug is “a lifesaving medication that saves lives.”
The A.M.A. has also called for the A.P.A., the U-S.
Food and Drug Administration, and the FDA to lower drug prices.
So far, no one has stepped up to take the fight to the drugmakers.
Tetromax, the oldest and cheapest of the three drugs, has sold for more than $50 million in the last year, according a Reuters report.
The Arapahoe County District Attorney, Dan Rochon, said Tetramavax is being unfairly marketed by the pharmaceutical industry.
Tetras new price of $120,000 will cost the families of the families who lost their lives, he said.
The fight over